NCT00868361View on ClinicalTrials.gov

A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

PHASE1TerminatedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Healthy

Interventions

DRUG

Talampanel (non-radiolabeled), [14C] Talampanel

50 mg capsule single dose

Trial Locations (1)

53704

Covance Clinical Pharmacology Inc., Madison

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Covance

INDUSTRY

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY